Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market Forecast: Value Set To Climb From $2.43 Billion To $3.23 Billion
The next-generation sequencing (ngs)-based molecular diagnostics market size has demonstrated robust expansion over recent years. It is projected to expand from $2.26 billion in 2025 to $2.43 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.6%. This historical growth can be attributed to factors such as increased genetic disorder testing, the evolution of high-throughput sequencing, a growing understanding of molecular diagnostics, broader adoption within clinical laboratories, and advancements in sequencing reagent technology.
The next-generation sequencing (ngs)-based molecular diagnostics market size is anticipated to undergo significant expansion in the upcoming years. It is projected to grow to $3.23 billion in 2030, at a compound annual growth rate (CAGR) of 7.3%. The drivers for this growth within the forecast period include the integration of AI and machine learning in diagnostics, the expansion of cloud-based genomic platforms, the development of portable and point-of-care sequencing devices, a rise in personalized medicine applications, and collaborations between diagnostics and biotech firms. Key trends for the forecast period encompass AI-assisted molecular diagnostics, cloud genomic analysis platforms, portable sequencing devices, the integration of bioinformatics pipelines, and rapid disease marker detection.
Get A Free Sample Report With In-Depth Market Insights:
Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market Demand Drivers: What’s Powering Industry Growth?
The escalating occurrence of infectious diseases is projected to drive the expansion of the next-generation sequencing (NGS)-based molecular diagnostics market in the future. These diseases are conditions caused by microorganisms such as bacteria, viruses, fungi, or parasites, which invade the body, multiply, and disrupt normal functions. The global prevalence of infectious diseases is increasing, with heightened travel and migration facilitating faster transmission of pathogens across regions and borders. Next-generation sequencing (NGS)-based molecular diagnostics offers comprehensive and precise pathogen analysis, assisting in the detection of infectious diseases. It also shortens diagnostic timelines by enabling simultaneous identification of various microorganisms, thereby improving treatment accuracy and overall patient care. An illustration of this trend is seen in data from February 2024, where the UK Health Security Agency, a UK-based government agency, noted that tuberculosis (a contagious bacterial infection primarily affecting the lungs) cases in England increased to 4,850 in 2023, marking a 10.7% rise from the 4,380 cases reported in 2022. Thus, the growing incidence of infectious diseases is a significant catalyst for the growth of the next-generation sequencing (NGS)-based molecular diagnostics market.
Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market Segments: Where Is Growth Concentrated?
The next-generation sequencing (ngs)-based molecular diagnostics market covered in this report is segmented –
1) By Type: Instruments, Reagents And Consumables, Software And Services, Panels And Assays, Sample Preparation Kits
2) By Application: Microbiology, Infectious Diseases, Oncology, Genetic Tests, Other Applications
3) By End User: Research Centers And Academics, Hospitals And Clinical Laboratories, Other End Users
Subsegments:
1) By Instruments: Benchtop Sequencers, High-Throughput Sequencers, Portable Or Handheld Sequencers, Clinical Or Diagnostic Sequencers, Automated Library Preparation Systems, Data Analysis And Bioinformatics Hardware
2) By Reagents And Consumables: Sequencing Reagents And Kits, Library Preparation Reagents, Target Enrichment Reagents, Amplification Reagents, Sequencing Flow Cells And Chips, Deoxyribonucleic Acid (DNA) Or Ribonucleic Acid (RNA) Extraction Reagents, Quality Control Reagents
3) By Software And Services: Data Analysis Software, Bioinformatics Pipelines, Cloud-Based Genomic Platforms, Clinical Interpretation Tools, Data Storage And Management Services, Custom Bioinformatics Services, Genomic Database Services
4) By Panels And Assays: Oncology Panels, Infectious Disease Panels, Carrier Screening Panels, Reproductive Health Panels, Rare Disease Or Genetic Disorder Panels, Pharmacogenomics Panels, Whole-Exome Or Whole-Genome Assays
5) By Sample Preparation Kits: Deoxyribonucleic Acid (DNA) Extraction Kits, Ribonucleic Acid (RNA) Extraction Kits, Library Preparation Kits, Target Enrichment Kits, Amplification And Cleanup Kits, Single-Cell Preparation Kits, Low-Input Or Degraded Sample Kits
Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market Innovation Trends: What Developments Are Reshaping The Industry?
Major companies operating in the next-generation sequencing (NGS)-based molecular diagnostics market are concentrating on developing sophisticated NGS-based panels, aiming to improve the accuracy, accessibility, and efficiency of genetic testing. NGS panels involve specific sets of genes or genomic regions that are analyzed concurrently using NGS technology to identify clinically significant mutations, facilitating quicker and more accurate molecular diagnostics. As an illustration, in April 2024, Pillar Biosciences, a US-based diagnostics company, secured FDA approval for its oncoReveal CDx pan-cancer solid tumor IVD kit, which examines 22 clinically relevant genes in a single multiplex reaction. Designed for integration with Illumina’s MiSeq Dx system, the panel provides a sample-to-report time of approximately 48 hours and can handle up to 46 clinical samples per run. Furthermore, OncoReveal CDx incorporates companion diagnostic claims for KRAS (relevant for EGFR-targeted therapy in colorectal cancer) and EGFR (for TKI therapy in non–small-cell lung cancer), thereby enabling more exhaustive and efficient detection of actionable genomic alterations to refine clinical decision-making.
Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market Company Landscape And Competitive Strategy
Major companies operating in the next-generation sequencing (ngs)-based molecular diagnostics market are Thermo Fisher Scientific, Siemens Healthineers AG, Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., Qiagen N.V., Amoy Diagnostics Co. Ltd., Tempus Labs Inc., Myriad Genetics Inc., Epigenomics AG, Precision for Medicine Inc., Invitae Corporation, NeoGenomics Laboratories Inc., Guardant Health Inc., Caris Life Sciences Inc., Foundation Medicine Inc., Oxford Nanopore Technologies Ltd., Freenome Inc., Burning Rock Biotech, Element Biosciences Inc., Asuragen Inc., Bionano Genomics Inc., Genomic Health Inc., TATAA Biocenter AB
View The Full Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market Report:
Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market Largest Region: Which Geography Holds The Biggest Share?
North America was the largest region in the next-generation sequencing (NGS)-based molecular diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation sequencing (ngs)-based molecular diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
